NDAORALTABLETPriority Review
Approved
Nov 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
5/8 — Partial
Priority Review
Drug data last refreshed 1m ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JULUCA is a fixed-dose oral combination of dolutegravir (integrase strand transfer inhibitor) and rilpivirine (non-nucleoside reverse transcriptase inhibitor) approved for HIV-1 treatment. It is indicated for use in treatment-experienced adults with HIV-1 infection who are virologically suppressed on a current antiretroviral regimen. The dual mechanism provides complementary viral suppression through distinct inhibitory pathways.
$0.392BPart D
PeakStable
12.2 years to LOEPeak lifecycle with $392M in Part D spending reflects mature market position; brand teams are focused on maximizing penetration within a stable indication rather than scaling rapid growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Study to Evaluate Pharmacokinetics, Safety and Tolerability of Dolutegravir and Rilpivirine (JULUCA™) 50 Milligram (mg)/25 mg Tablets in Healthy Subjects of Japanese Descent
Started Jun 2019
16 enrolled
HIV Infections
Why This Matters for Your Career
Worked on JULUCA at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.